High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
Launched by ASTRAZENECA · Oct 18, 2005
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent
- • Stable hypertension defined as no new antihypertensive medication started within 6 weeks of Visit 1
- • Minimum 6-month history of hypertension and primary glomerular disease
- • Hypertensive nephrosclerosis
- • Diabetic nephropathy with stable proteinuria as defined by ≥ 1g/24 hours on more than one occasion within 6 months prior to Visit 1
- Exclusion Criteria:
- • Persistent hypertension
- • New anti-hypertensive medications started within 6 weeks of Visit 1
- • Significant cardiac disease or Liver disease
- • Females of childbearing potential without reliable contraception
- • Pregnant women and women who are breast-feeding
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Halifax, Nova Scotia, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Kitchener, , Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
Oshawa, Ontario, Canada
Sudbury, Ontario, Canada
Laval, Quebec, Canada
Ste Foy, Quebec, Canada
Mississauga, Ontario, Canada
Calgary, Alberta, Canada
Kelowna, British Columbia, Canada
Saskatoon, Saskatchewan, Canada
Scarborough, Ontario, Canada
Courtice, Ontario, Canada
Thunder Bay, Ontario, Canada
Greenfield Park, Quebec, Canada
Weston, Ontario, Canada
Oakville, Ontario, Canada
St. John, Newfoundland And Labrador, Canada
Richmond Hill, Ontario, Canada
Timmins, Ontario, Canada
Quebec City, Quebec, Canada
Patients applied
Trial Officials
Kazi Borkowski, PhD
Study Director
AstraZeneca
Norman MuirHead, MD
Principal Investigator
London HSC
Ellen Burgess, MD
Principal Investigator
Foothills Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials